Nozaki K, Matsushima H, Obikane H, Nishimoto R, Tanaka R, Morishige T, Masuda T, Kume H. Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents.
IJU Case Rep 2023;
6:329-333. [PMID:
37928277 PMCID:
PMC10622209 DOI:
10.1002/iju5.12611]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2023] [Accepted: 07/11/2023] [Indexed: 11/07/2023] Open
Abstract
Introduction
Disseminated carcinomatosis of the bone marrow in prostate cancer is rare and has a poor prognosis. Although strong evidence suggests that novel hormonal agents improve the prognosis of metastatic prostate cancer, their effectiveness in cases of disseminated carcinomatosis of the bone marrow remains unclear.
Case presentation
We encountered two cases of prostate cancer with disseminated carcinomatosis of the bone marrow at the time of initial diagnosis. One patient was treated with enzalutamide, abiraterone, docetaxel, cabazitaxel, denosumab, and radium-223 and died 38 months after the initial diagnosis. The other patient was treated with apalutamide and denosumab, and had progression-free survival for 17 months after the initial diagnosis.
Conclusion
These results suggest that novel hormonal agents may improve the prognosis of prostate cancer even in patients with disseminated carcinomatosis of the bone marrow.
Collapse